Tag Archives: oncology

Post-Con BIO CEO Company Snapshot: Immunovaccine

Immunovaccine-logo-PMS

A few weeks ago, the BIO CEO & Investor Conference concluded in New York City. With a 30% increase in One-on-One Partnering meetings and sold out company presentations, industry execs gathered to do business, and hear the latest from innovative companies. As a precursor to the event, the company snapshot campaign highlighted a few of the companies who would be participating onsite. This year, the snapshot feature concludes with an interview from Marc Mansour, Ph.D., Chief Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO CEO: Five Prime Therapeutics Company Snapshot

fiveprime

Five Prime Therapeutics is another company that will be presenting at next week’s BIO CEO & Investor Conference. They will be among 20 other presenters at the event who debuted an IPO in the last two years. Read below to learn more about their work, and what to expect from them at the event. Company Snapshot What is your company’s lead product or technology? Five Prime focuses on discovering and developing novel protein therapeutics for Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BIO Investor Forum Company Snapshot: Opsona Therapeutics

opsona115x76

Opsona Therapeutics will be participating in the upcoming BIO Investor Forum, and will be giving a presentation on their work in the autoimmune/inflammatory diseases and oncology space (among other indications). To learn more about their company, please read one of our final company snapshots below. Company Snapshot What is your company’s lead product or technology? Opsona’s lead product OPN-305 is a fully humanized monoclonal IgG4 antibody targeting Toll-like-receptor-2 (TLR2), which is in clinical development as Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Investor Forum Company Snapshot: DLVR Therapeutics

DLVR

DLVR Therapeutics will be presenting in the Discovery Company Track at the upcoming BIO Investor Forum. Below, this early-stage company based in Ontario, answers our snapshot questions to provide attendees and readers with more perspective on their work. Company Snapshot What is your company’s lead product or technology?  DLVR is developing an innovative nanoparticle for delivery of nucleotides, such as small interfering RNA (siRNA). Our key differentiator is the synthesis of an HDL-mimetic phospholipid-based particle Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , ,